Inovio Eyes Expanded Asian Opportunities, Presence Via Korea Dual Listing
Keen Investor Interest In Country's Bioventure Sector
Inovio is poised to become the first US-listed company to dual-list in South Korea, as CEO tells Scrip it is seeking to increase its presence and find new opportunities in Asia, while benefiting from strong investor interest in the country’s "very exciting" and vibrant biotech industry.
You may also be interested in...
South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities.
Inovio's new licensing deal for its most advanced pipeline asset gives the US firm not only its first partner for the cervical dysplasia vaccine but also a presence in a major emerging market.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.